医学临床研究
  2025年7月17日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (2): 205-207    DOI: 10.3969/j.issn.1671-7171.2022.02.013
  论著 本期目录 | 过刊浏览 | 高级检索 |
吡咯替尼联合化疗治疗晚期HER2阳性乳腺癌的疗效
赵晓宇, 宋忠花, 曲向晖
山东省立第三医院全科医学科,山东 济南 250031
Efficacy of Pyrrotinib Combined with Chemotherapy in the Treatment of HER2 Positive Advanced Breast Cancer
ZHAO Xiao-yu, SONG Zhong-hua, QU Xiang-hui
Department of General Medicine, Shandong Provincial Third Hospital Jinan,Jinan Shandong 250031
全文: PDF (1166 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨吡咯替尼联合化疗治疗晚期人表皮生长因子受体2(HER2)阳性乳腺癌患者的疗效。【方法】本院收治的72例HER2阳性晚期乳腺癌患者,随机分为观察组和对照组,每组各36例。对照组采用常规化疗进行治疗,观察组采用吡咯替尼联合化疗治疗。对比两组患者化疗药物使用情况、近期临床疗效、治疗期间不良反应及生存情况。【结果】观察组临床控制率为69.44%(25/36),显著高于对照组的47.22%(17/36)(P<0.05)。观察组与对照组恶心呕吐、脱发、乏力等不良反应发生率相比较,差异均无统计学意义
(P>0.05)。随访6个月,对照组、观察组存活率分别为80.00%、88.24%,两组生存曲线比较差异无统计学意义(P>0.05)。【结论】吡咯替尼联合化疗治疗晚期HER2阳性乳腺癌患者,可提高临床控制率且安全可靠,但术后随访6个月患者生存率无明显提高。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
赵晓宇
宋忠花
曲向晖
关键词 乳腺肿瘤/治疗受体,表皮生长因子受体,erbB-2抗肿瘤联合化疗方案    
Abstract:【Objective】To explore the efficacy and survival status of pyrrotinib combined with chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer. 【Methods】A total of 72 patients with HER2 positive advanced breast cancer admitted to our hospital was randomly divided into observation group and control group, 36 cases in each group. The control group was treated with routine chemotherapy, and the observation group was treated with pyrrotinib combined with chemotherapy. The use of chemotherapy drugs, short-term clinical efficacy, adverse reactions and survival of the two groups were compared.【Results】The clinical control rate in the observation group was 69.44% (25/36), which was significantly higher than 47.22% (17/36) in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions such as nausea, vomiting, hair loss and fatigue between the observation group and the control group (P>0.05). After 6 months of follow-up, the survival rates of the control group and the observation group were 80.00% and 88.24% respectively. There was no significant difference in the survival curve between the two groups (P>0.05). 【Conclusion】Pyrrotinib combined with chemotherapy in the treatment of HER2 positive advanced breast cancer patients can improve the clinical control rate and is safe and reliable. However, the survival rate of patients with follow-up of 6 months after operation is not significantly improved.
Key wordsBreast Neoplasms/TH    Receptor,Epidermal Growth Factor    Receptor,ErbB-2    Antineoplastic Combined Chemotherapy Protocols
收稿日期: 2021-06-28     
中图分类号:  R737.9  
引用本文:   
赵晓宇, 宋忠花, 曲向晖. 吡咯替尼联合化疗治疗晚期HER2阳性乳腺癌的疗效[J]. 医学临床研究, 2022, 39(2): 205-207.
ZHAO Xiao-yu, SONG Zhong-hua, QU Xiang-hui. Efficacy of Pyrrotinib Combined with Chemotherapy in the Treatment of HER2 Positive Advanced Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2022, 39(2): 205-207.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.02.013     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I2/205
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn